REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
← catalyst calendarNCT07675824 · readout in 1,070 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
271estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-23 | estimated | When the study began enrolling |
| Primary completion | 2029-07-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-16 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Primary Open Angle Glaucoma (POAG)
- Ocular Hypertension (OHT)
Intervention
- Drug: REGN22530
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Treatment Emergent Adverse Events (TEAEs)
measured Up to week 16
Change from baseline in mean diurnal IOP in the study eye
measured At day 85
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed